Human2017-05-25
Epilepsy · CBD
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
The New England journal of medicine · PMID 28538134
Randomized placebo-controlled add-on trial
- Studied preparation
- Purified CBD oral solution added to existing antiseizure treatment.
- Population / model
- 120 children and young adults with Dravet syndrome and drug-resistant seizures.
- What was observed
- The tested formulation reduced convulsive-seizure frequency relative to placebo; adverse events were more frequent.
Interpretation limit
A specific severe epilepsy population and prescription-style formulation; findings do not establish benefits or safety of retail CBD oils.
Journal publication · Source checked 2026-10-25
Sources, registration and terms
Citation and publication date recorded; peer-review/preprint status not separately classified.
No full-text link recorded here; a DOI does not promise free full text.
Registry state is a dated sponsor report; it does not confirm current recruitment or establish benefit.
- Results paper for this recorded registration
NCT02091375 registry context · Original NCT02091375
Results tables posted in registry
Status: Completed — sponsor-reported. Registry updated 2022-09-28; source checked 2026-10-25.
CBD / cannabidiol · Human study · Registered trial · Primary versus secondary outcome